Repligen (RGEN): CEO sold ~$536K
Olivier Loeillot, CEO at Repligen, sold ~$536K of Repligen shares.
- ~$536K
- Approx. value · 3,832 sh @ $140.00
- 54K
- Holds after · shares reported
- Traded
- Apr 21, 2026
- Filed
- Apr 22, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Feb 24, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 21, 2026 · this disclosureInsiderCEO sold ~$536K of RGEN shares in the open market
What came next
- May 5, 2026Company filing · Form 8-K · ResultsReported its results
- May 28, 2026Federal contract · $175K obligatedDepartment of Health and Human Services awarded REPLIGEN CORP: $175K obligated to date
- Jun 25, 2026InsiderCFO sold ~$106K of RGEN shares in the open market
- Jul 16, 2026InsiderCFO sold ~$80K of RGEN shares in the open market
- Jul 21, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 2 more items)
- Jul 28, 2026Company filing · Form 8-K · ResultsReported its results
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Repligen
For Repligen, OQRO holds 9 insider filings (SEC Form 4 or Form 144) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RGEN page.
Other recent filings by Olivier Loeillot, Chief Executive Officer
- SEC Form 4 at Repligen (RGEN)Oct 6, 2026
- SEC Form 4 at Repligen (RGEN)Oct 6, 2026
- SEC Form 4 at Repligen (RGEN)Sep 26, 2026
- SEC Form 4 at Repligen (RGEN)Sep 26, 2026
- SEC Form 4 at Repligen (RGEN)Sep 23, 2026
The full history of Olivier Loeillot, Chief Executive Officer is on the profile page.
How this filing works
Explore the data
Other disclosures at Repligen
- SEC Form 4Oct 6, 2026
- SEC Form 4Oct 6, 2026
- SEC Form 144Oct 5, 2026
- SEC Form 144Oct 5, 2026
- SEC Form 4Sep 26, 2026
- SEC Form 4Sep 26, 2026
Everything OQRO holds on this company is on its RGEN page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
